ES2540453B1 - Micropartículas con EGF, procedimiento de preparación y uso - Google Patents

Micropartículas con EGF, procedimiento de preparación y uso Download PDF

Info

Publication number
ES2540453B1
ES2540453B1 ES201590050A ES201590050A ES2540453B1 ES 2540453 B1 ES2540453 B1 ES 2540453B1 ES 201590050 A ES201590050 A ES 201590050A ES 201590050 A ES201590050 A ES 201590050A ES 2540453 B1 ES2540453 B1 ES 2540453B1
Authority
ES
Spain
Prior art keywords
microparticles
preparation
egf
use procedure
refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201590050A
Other languages
English (en)
Other versions
ES2540453R1 (es
ES2540453A2 (es
Inventor
Eusebio GAINZA LAFUENTE
Garazi GAINZA LUCEA
Oihane IBARROLA MORENO
Silvia VILLULLAS RINCON
Del Pozo Perez ANGEL
Jose Luis Pedraz Muñoz
Rosa Maria Hernandez Martin
Manuela Igartua Olaechea
Alfredo GOMEZ MENGOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Pharmaceutical SA
Original Assignee
Praxis Pharmaceutical SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Pharmaceutical SA filed Critical Praxis Pharmaceutical SA
Publication of ES2540453A2 publication Critical patent/ES2540453A2/es
Publication of ES2540453R1 publication Critical patent/ES2540453R1/es
Application granted granted Critical
Publication of ES2540453B1 publication Critical patent/ES2540453B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Micropartículas con EGF, procedimiento de preparación y uso.#La presente invención se refiere a micropartículas que comprenden polímeros biocompatibles y el factor de crecimiento epidérmico. Asimismo, se refiere al método de preparación de dichas micropartículas y a su uso para promover la cicatrización de heridas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
    imagen2
ES201590050A 2012-11-30 2013-12-02 Micropartículas con EGF, procedimiento de preparación y uso Expired - Fee Related ES2540453B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382476.5A EP2737895A1 (en) 2012-11-30 2012-11-30 Microparticles with EGF, method of preparation and use
PCT/ES2013/070833 WO2014083233A1 (es) 2012-11-30 2013-12-02 Micropartículas con egf, procedimiento de preparación y uso

Publications (3)

Publication Number Publication Date
ES2540453A2 ES2540453A2 (es) 2015-07-09
ES2540453R1 ES2540453R1 (es) 2016-02-23
ES2540453B1 true ES2540453B1 (es) 2016-09-07

Family

ID=47623891

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201590050A Expired - Fee Related ES2540453B1 (es) 2012-11-30 2013-12-02 Micropartículas con EGF, procedimiento de preparación y uso

Country Status (3)

Country Link
EP (1) EP2737895A1 (es)
ES (1) ES2540453B1 (es)
WO (1) WO2014083233A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287242A (zh) * 2015-11-11 2016-02-03 浙江元研生物科技有限公司 一种含人干细胞生长因子的护肤品及其制备方法
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219998A (en) 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética

Also Published As

Publication number Publication date
WO2014083233A1 (es) 2014-06-05
EP2737895A1 (en) 2014-06-04
ES2540453R1 (es) 2016-02-23
ES2540453A2 (es) 2015-07-09

Similar Documents

Publication Publication Date Title
ES2533145B1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
BR112015030525A2 (pt) nanopartícula, kit, método de preparação de uma nanopartícula, e uso da nanopartícula
EP2846714A4 (en) METHOD AND DEVICE FOR FIXING TISSUES TO BONE, INCLUDING THE PROVISION AND USE OF A NOVEL NODLESS NEEDLE ANCHOR SYSTEM
EP3079604A4 (en) Method and apparatus for attaching tissue to bone, including the provision and use of a novel knotless suture anchor system
CL2014000254A1 (es) Hormona de crecimiento de accion prolongada y metodo para producir la misma
EP2967552B8 (en) Tissue capturing bone anchor
CO6960513A2 (es) Ancla quirúrgica
ES2421956B1 (es) Nueva forma cristalina de sulfato de sitagliptina
EP3030176A4 (en) Bipolar surgical instrument with tissue stop
DK2994173T3 (en) Wound healing and tissue engineering
FR3008885B1 (fr) Dispositif chirurgical notamment pour la pose de prothese de cordage mitrale
BR112015000534A2 (pt) método para a preparação de 2,4-dihidroxibutirato, microrganismo, organismo e uso
BR112014028413A2 (pt) usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 .
WO2014018747A3 (en) Glycoproteins with anti-inflammatory properties
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
UY34385A (es) Ésteres lábiles de agroquímicos para una liberación controlada y reducción del desplazamiento fuera del sitio de acción
ES2567082T9 (es) Transformador de turbina eólica
BR112014026565A2 (pt) formulação, uso de uma formulação, e, processo para produzir uma formulação
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
CL2014002908A1 (es) Método para la preparación de 2-(2,3-dimetilfenil)-1-propanal y sus usos.
CL2016001369A1 (es) Procedimiento para la preparación de un emulsionado de aceite en agua
ES2540453B1 (es) Micropartículas con EGF, procedimiento de preparación y uso
CO7200264A2 (es) Fluoruros de fluorpicolinoilo y procesos para su preparación
BR112014030949A2 (pt) "composição, processo para o tratamento cosmético e uso de uma composição"
DE112014005425A5 (de) Patiententisch zur Herstellung von NMR- und/oder CT-Aufnahmen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2540453

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160907

FD2A Announcement of lapse in spain

Effective date: 20210915